Related Experiment Videos

Reversible diplopia induced by high-dose intravenous IL-2 therapy

Jayaram S Bharadwaj¹, Deborah T Blumenthal, Wolfram E Samlowski

¹The University of Utah Cancer Immunotherapy Program, UT, USA.

Clinical Advances in Hematology & Oncology : H&O

|September 16, 2005

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Prospective randomized trial of tumor-treating fields with chemoradiation in newly diagnosed glioblastoma.

Neuro-oncology advances·2026

Rethinking treatment de-escalation in elderly glioblastoma: Lessons from a multicenter real-world cohort.

Neuro-oncology advances·2026

Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Oncology·2025

In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination.

Journal for immunotherapy of cancer·2025

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.

Neuro-oncology·2024

A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine.

Nature communications·2024

See all related articles